Skip to content

Blood Flow Restriction Training for Age-Related Sarcopenia

The Efficacy of Blood Flow Restriction Training in Elderly Patients With Sarcopenia.

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06986395
Enrollment
40
Registered
2025-05-23
Start date
2025-05-31
Completion date
2025-09-10
Last updated
2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia in Elderly

Brief summary

Brief Title: Safe Exercise for Age-Related Muscle Loss in Hospitalized Seniors Summary: This study compares two exercise methods to help older hospital patients (age 65+) rebuild muscle strength after being diagnosed with sarcopenia (age-related muscle loss). We want to know if using special pressure cuffs during light exercise works better than traditional strength training alone. Who Can Join: Hospitalized seniors with stable health conditions Excludes those with severe disabilities, dementia, or certain blood circulation problems What We'll Do: 40 participants will be randomly assigned to either: Traditional Training Group: Uses weights/bands at 65-75% max capacity Arm/leg exercises 3x/week for 4 weeks Pressure Cuff Training Group: Uses special cuffs on arms/thighs during lighter exercises (20% max capacity) Same exercise frequency with controlled pressure for safety What We'll Measure: Handgrip strength (main test at 0/4/12 weeks) Walking speed, balance tests, quality of life surveys Any side effects like dizziness/nausea Safety First: Doctors will check your health before starting. Nurses will monitor every session. We use medical-grade cuffs with safe pressure limits (arm: 80-100mmHg, thigh: 150-200mmHg). You can stop anytime if uncomfortable. Why This Matters: This could help hospitalized seniors regain strength faster using gentler exercises. All activities are supervised by rehabilitation specialists at West China Hospital, with ethics committee approval (IRB number required).

Interventions

Standard progressive resistance exercise at 65-75% 1RM intensity using weights/elastic bands

OTHERConventional Resistance Training (CRT)

Standard progressive resistance exercise at 65-75% 1RM intensity using weights/elastic bands

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
65 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Hospitalized patients aged ≥65 years * Diagnosed with sarcopenia per EWGSOP2019 criteria * Acute medical conditions stabilized for ≥4 weeks (e.g., resolved infections, controlled heart failure)

Exclusion criteria

* Severe disability (Barthel Index ≤40) * Significant cognitive impairment (MMSE ≤18) or major psychiatric disorders (DSM-5 criteria) * Contraindications to blood flow restriction training: * History/predisposition to deep vein thrombosis * Coagulopathy (INR \>1.5, platelets \<100×10⁹/L) * Symptomatic varicose veins (CEAP class C4-C6) * Uncontrolled hypertension (BP \>160/100 mmHg) * Chronic lymphedema (ISL stage II-III) * Peripheral artery disease (ABI ≤0.7) * Active systemic infection (CRP \>10 mg/L) * Malignancy (except non-melanoma skin cancer) * Severe renal impairment (eGFR \<30 mL/min/1.73m²) * Acute coronary syndrome within 3 months

Design outcomes

Primary

MeasureTime frame
Change in Handgrip StrengthBaseline (Week 0), Post-intervention (Week 4), Follow-up (Week 12)

Secondary

MeasureTime frame
6-Meter Walking SpeedBaseline (Week 0), Follow-up (Week 12)
Short Physical Performance Battery (SPPB)Baseline (Week 0), Post-intervention (Week 4), Follow-up (Week 12)
Timed Up and Go Test (TUG)Baseline (Week 0), Post-intervention (Week 4), Follow-up (Week 12)
MBIBaseline (Week 0), Post-intervention (Week 4), Follow-up (Week 12)

Contacts

Primary Contactyu liang
1536569213@qq.com+86 13982250862

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026